Aarkstore - Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Aarkstore Enterprise

5th December 2014

Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Browse Full Report @ http://www.aarkstore.com/pharmaceuticals-healthcare/60345/hepatitis-b-therapeuticspipeline-assessment-and-market-forecasts Published: Mar 2012 | No. Of Pages: 103 Pages PDF: $ 3995 | Site Licence : $ 7990 | Enterprise Wide Licence : $ 11985

Summary

The industry analysis specialist, has released its new report, “Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global hepatitis B therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis B therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by GlobalData’s team of industry experts. GlobalData’s analysis shows that the global hepatitis B therapeutics market stood at $2,018.7m in 2006 and grew at a Compound Annual Growth Rate (CAGR) of 8.6% to reach $3,056.0m in 2011. GlobalData forecasts that the global hepatitis B therapeutics market will grow at a slow rate with a CAGR of 4.8% over the forecast period to reach $4,441.3m by 2019. The low growth in the global hepatitis B therapeutics market can be attributed to the high vaccination coverage rates in developed countries, resulting in lower incidence rates of hepatitis B. The hepatitis B therapeutics market is also set to witness the patent expiry of most of the nucleoside analogues between 2013 and 2017. The patent expiry of the immunologic Pegasys (peginterferon alfa-2a) in...